
23andMe (ME) shares crashed roughly 50% on Monday, March 24 after the personal genomics and biotech firm filed for Chapter 11 bankruptcy in the Eastern District of Missouri.
The DNA kit company that once commanded a valuation of about $6 billion will now sell its assets and use the proceeds to address its outstanding legal liabilities.